Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase 2a clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. It is also discovering and developing the ADX-096, a C3d  CR1 fusion protein, and other earlier stage assets, including C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.

Q32 Bio Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX) and Q32 Bio (QTTB) wit...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	QTTB	$15.15	-1.43%	311.85K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	QTTB	$15.15	-1.4%	311.85K
3
4
5
6

QTTB

Get Q32 Bio Inc. Data in Excel

Get Q32 Bio Inc. Data in Excel